Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
SAN DIEGO, May 25, 2017 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases, today announced presentations for its two most advanced clinical stage oncology product candidates, TRC105 and TRC102, at the upcoming American Society of Clinical Oncology (ASCO) annual meeting to be held June 2-6, 2017, in Chicago, Illinois.
The following is a summary of the four presentations that will be given at ASCO:
| Poster Discussion Presentations | |
| Title: | A Phase I Trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients |
| with solid tumors and lymphomas (Abstract #2518) | |
| Presenter: | Robert S. Meehan, MD, National Cancer Institute |
| Location: | S Hall A, Poster Board 10 (poster display) |
| Arie Crown Theater (poster discussion) | |
| Date/Time: | Monday, June 5, 2017, 8:00 AM – 11:30 AM, Central time (poster display) |
| Monday, June 5, 2017, 11:30 AM – 12:45 PM, Central time (poster discussion) | |
| Title: | NCCTG N1174: Phase I/comparative randomized Phase II trial of TRC105 plus |
| bevacizumab versus bevacizumab in recurrent glioblastoma (GBM) (Abstract #2023) | |
| Presenter: | Evanthia Galanis, MD, Mayo Clinic |
| Location: | S Hall A, Poster Board 265 (poster display) |
| S404 (poster discussion) | |
| Date/Time: | Monday, June 5, 2017, 1:15 PM – 4:45 PM, Central time (poster display) |
| Monday, June 5, 2017, 4:45 PM – 6:00 PM, Central time (poster discussion) | |
| General Poster Presentations | |
| Title: | Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF |
| therapy (Abstract #11546) | |
| Presenter: | Yingmiao Liu, Ph.D., Duke University Medical Center |
| Location: | S Hall A, Poster Board 246 |
| Date/Time: | Saturday, June 3, 2017, 1:15 PM – 4:45 PM, Central time |
| Title: | TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus |
| pazopanib alone in patients with advanced angiosarcoma (Abstract #TPS11081) | |
| Presenter: | Robin Lewis Jones, BSc, MB, MRCP, MD, Royal Marsden Hospital |
| Location: | S Hall A, Poster Board 403a |
| Date/Time: | Sunday, June 4, 2017, 8:00 AM – 11:30 AM, Central time |
About Carotuximab (TRC105)
TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in one Phase 3 and multiple Phase 2 clinical trials sponsored by TRACON or the National Cancer Institute for the treatment of solid tumors in combination with VEGF inhibitors. TRC105 has received orphan designation for the treatment of soft tissue sarcoma in both the U.S. and EU. The ophthalmic formulation of TRC105, DE-122, is currently in a Phase 1/2 trial for patients with wet AMD. For more information about the clinical trials, please visit TRACON’s website at www.traconpharma.com/clinical_trials.php.
About TRC102
TRC102 (methoxyamine) is a novel, clinical-stage small molecule inhibitor of the DNA base excision repair pathway, which is a pathway that causes resistance to alkylating and antimetabolite chemotherapeutics. TRC102 is currently being studied in multiple Phase 1 and Phase 2 clinical trials sponsored by the National Cancer Institute or Case Comprehensive Cancer Center. For more information about the clinical trials, please visit TRACON’s website at www.traconpharma.com/clinical_trials.php.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
